Cristália signs licensing deal for Formosa’s APP13007

Cristália has signed an agreement to license exclusive rights to market Formosa Pharmaceuticals’ APP13007 in Brazil.

Jan 29, 2024 - 18:00

Cristália signs licensing deal for Formosa’s APP13007

Cristália has signed an agreement to license exclusive rights to market Formosa Pharmaceuticals’ APP13007 in Brazil.

Read the original article

Tags:

Previous Article

Cell and gene therapies – top pharmaceutical industry trend to watch for 2024

FDA grants priority review for Daiichi Sankyo-AstraZeneca’s Enhertu

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

How a conservative, gun-toting doctor defended abortion access in Appalachia

How a conservative, gun-toting doctor defended abortion...

Sep 6, 2023

STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO

STAT+: BIO selects rare disease advocate, biotech execu...

Dec 5, 2023

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

China NMPA grants approval for GenFleet’s fulzerasib to...

Aug 27, 2024